Clinics are combining peptides with lab results and patient-reported outcomes to design protocols that target aging, recovery, metabolism, or cognition with greater precision
Dose selection in the research literature varies with the application: musculoskeletal-injury studies commonly report 200250 g twice daily near the affected site, while gastrointestinal-focused protocols use 250500 g once or twice daily, subcutaneously
Across these applications, GHKCu functions as a research reagent for dissecting biochemical and cellular pathways
There is no universally recommended human dosing protocol for BPC-157, no established cycle length, and no clinically confirmed injection frequency
For IV injection the vitamin C is diluted with a saline solution
Cerebrolysin reduces astrogliosis and axonal injury and enhances neurogenesis in rats after closed head injury